A leading pharmaceutical company in Amyotrophic Lateral Sclerosis (ALS) is interested in speaking with startups whose technology could contribute to very early diagnosis of the disease. If your startup has developed novel approaches to measuring any of the Early Symptoms of ALS or Early Experiences of ALS Patients (listed separately below), please consider reaching out through this opportunity.
Selection will be made in June and meeting series will start in mid-July. Linking into the series will be people from the company involved with digital technologies to enhance performance of established and newer therapies. In the case that there is common interest, from the company’s standpoint, this could translate into a partnership or investment.
Early Symptoms of ALS (usually in arms or hands, but sometimes in a leg)
Early Experiences of ALS Patients (can include)
Proof of concept already achieved in a neurological disease is preferred, but not required. Technologies that can be used through a platform that runs on mobile devices is also preferred. The company is interested in tools suitable for home use or point of care. Below are some advanced examples.
Advanced Examples
In your response, please indicate
In your response, please indicate
Disclaimer: MIT Startup Exchange can make introductions that ideally provide open ended discussions in order to share mutual interests and potentially create common ground that incite the parties to collaborate. MIT Startup Exchange introductions may eventually lead to mutual partnerships, but that is not in any way guaranteed by MIT, MIT Corporate Relations, MIT Industrial Liaison Program (ILP) or MIT Startup Exchange, which takes no responsibility for these outcomes and no formal part in such discussions following our introduction. MIT Startup Exchange and its activities and events are not for purposes of soliciting investment or offering securities.